2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03
Dowlati A, Chiang A, Cervantes A, Babu S, Hamilton E, Wong S, Tazbirkova A, Sullivan I, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar S. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03. Journal Of Thoracic Oncology 2025 PMID: 39755168, DOI: 10.1016/j.jtho.2024.12.028.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsInvestigator-assessed objective response rateExtensive-stage SCLCObjective response rateProgression-free survivalPlatinum-sensitive diseaseSecond-line treatmentSacituzumab govitecanOverall survivalTreatment-related treatment-emergent adverse eventsExtensive-stage small cell lung cancerBlinded independent central review assessmentPhase 2 open-label studySmall cell lung cancerPlatinum-resistant diseaseSolid Tumors versionResponse Evaluation CriteriaPlatinum-based chemotherapySecond-line therapyCell lung cancerStudy of solid tumorsPartial responsePlatinum-sensitiveNeutropenic sepsisSecond-line
2024
OA04.04 Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer
Dowlati A, Chiang A, Cervantes A, Babu S, Hamilton E, Wong S, Tazbirkova A, Sullivan I, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar S. OA04.04 Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s16. DOI: 10.1016/j.jtho.2024.09.034.Peer-Reviewed Original Research
2023
1990MO Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial
Dowlati A, Cervantes A, Babu S, Hamilton E, Wong S, Tazbirkova A, Sullivan I, de Lummen C, Italiano A, Patel J, Mekan S, Wu T, Chiang A. 1990MO Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial. Annals Of Oncology 2023, 34: s1061-s1062. DOI: 10.1016/j.annonc.2023.09.1221.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply